CDKN2A and malignant glioma: In the present study, we have demonstrated that p27KIPl shows a greater antitumour effect than the other CDKIs (p16INK4A, p18INK4C, p19INK4D or p21WAF1/CIP1) against six human malignant glioma cell lines.